Eurofins MWG Operon extends its gene synthesis business with the acquisition of Entelechon

Eurofins MWG Operon, the genomics division of Eurofins Scientific, the global leader in bio-analytical testing, announces the acquisition of Entelechon GmbH. Entelechon is a globally operating provider of gene synthesis, serving the pharmaceutical industry as well as academic and public research institutes.

Founded in 1999 in Regensburg, Germany, Entelechon was one of the first companies specialised in commercial gene synthesis and has focused on advanced genomics and proteomics projects bringing broad experience in the fields of gene optimisation and synthesis.

As part of this transaction, the Entelechon gene synthesis business and the brand "Entelechon" will be integrated into the Eurofins MWG Operon gene synthesis business unit starting from June 1, 2013, resulting in an extremely powerful combined genomic services platform.

"The acquisition through Eurofins should generate considerable synergies and additional value to our customers," says Markus Fischer, Managing Director of Entelechon GmbH who will actively contribute to the integration of Entelechon into Eurofins, while remaining CEO of PolyQuant GmbH, a spin-off of Entelechon involved in protein expression and quantitative proteomics. "In view of gene optimisation, the combined platform GENEius 2.0 of both companies, has become even more effective and powerful than the former individual solutions of each party."

"Entelechon is an excellent strategic fit with Eurofins MWG Operon' genomic service offering and their competence on gene synthesis services and synthetic biology complements our DNA synthesis and sequencing units in an excellent way, while providing us with additional tools to serve the fast growing applied genetics markets", says Bruno Poddevin, Vice President of Eurofins MWG Operon. "The acquisition of Entelechon is a next step to further grow the business and strengthen our position as one of the market leaders in genomic services."

---

---